Publication
Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugGemcitabinecivic_curation1.00
- drugPaclitaxelcivic_curation1.00
- drugVinorelbinecivic_curation1.00
- geneRRM1civic_curation1.00
- variantRRM1 Underexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23038758
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RRM1 Underexpression2 | ||||||||
| Cisplatin + Gemcitabine + PaclitaxelCombination | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID12044The study began with a total of 443 patients with advanced NSCLC that were randomly assigned to either regimen A (paclitaxel and cisplatin with gemcitabine) or regimen B (cisplatin and vinorelbine). R… (full text at CIViC) PMID 23038758 · Vilmar et al., 2013 · Open in CIViC | civic |
| Gemcitabine + Paclitaxel + VinorelbineSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID5599The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 2… (full text at CIViC) PMID 23038758 · Vilmar et al., 2013 · Open in CIViC | civic |